Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy-Reference-Cited by-同舟云学术

Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy

Published:2022-06-01 Issue:6 Volume:322 Page:H1014-H1027
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

Malhi Naseeb K.¹^ORCID,Allen Claire L.¹,Stewart Elizabeth²^ORCID,Horton Katherine L.¹^ORCID,Riu Federica¹,Batson Jennifer²^ORCID,Amoaku Winfried³,Morris Jonathan C.⁴^ORCID,Arkill Kenton P.¹^ORCID,Bates David O.¹²⁵^ORCID

Affiliation:

1. Tumour and Vascular Biology Laboratories, Division of Cancer and Stem Cells, Centre for Cancer Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, United Kingdom

2. Exonate Limited, Duxford, United Kingdom

3. Division of Clinical Neuroscience, Department of Ophthalmology, School of Medicine, University of Nottingham, Nottingham, United Kingdom

4. School of Chemistry, University of New South Wales, Sydney, New South Wales, Australia

5. COMPARE, University of Birmingham and University of Nottingham Midlands, Nottingham, United Kingdom

Abstract

VEGF-A165a splicing is induced by hyperglycemia through PKC-mediated activation of SRPK1 in RPE cells, increasing their permeability and angiogenic capability. SRPK1 inhibitors can be given as eye drops to reduce retinal permeability and edema in diabetic retinopathy.

Funder

Exonate Ltd

British Heart Foundation

National Eye Research Centre

UKRI | Medical Research Council

Publisher

American Physiological Society

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00001.2022

Reference53 articles.